Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.5 (
thrombin
)
33,306
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Possible increased activation of the coagulation pathway was measured in a group of patients with neoplastic diseases. In addition to standard tests, the
thromboplastin
generation test,
thrombin
generation test and immunologic and coagulant activities of both Factor VIII and antithrombin III were utilized in the evaluation. The correlation between immuno-Factor VIII (VIII-Ag) and its clotting activity (VIII-C1) was good (r = 0.83). In contrast, this was not the situation for antithrombin III-Ag and its clotting activity.
Thromboplastin
generation was accelerated in 60% and
thrombin
generation was accelerated in 40% of the patients. Fibrinogen was elevated in half the cases: in most of these patients,
thrombin
times were slightly prolonged. These results indicate that some patients who have cancer have abnormal clotting patterns and are often in a potentially hypercoagulable state that is reflected by the
thromboplastin
generation test,
thrombin
generation test, and high levels of Factor VIII (both VIII-Ag and VIII-C1).
...
PMID:Antithrombin III and Factor VIII in patients with neoplasms. 87
Heparin activity was assessed in 11 patients who underwent extracorporeal circulation for open-heart surgery. The activated partial
thromboplastin
time (A-PTT),
thrombin
time, protamine sulphate titration and factor Xa inhibition assay were used. The patients received heparin 3 mg/kg body weight, and 20 mg/450 ml blood was added to the pump. When the operative procedure was extended beyond 100 minutes patients received an additional 1,5 mg heparin/kg body weight. Protamine sulphate in a dose of 1,5 mg/1 mg heparin, was given to neutralize the heparin activity. The A-PTT was the easiest test which gave reliable results. The factor Xa inhibition assay measured heparin levels most precisely and mirrored the A-PTT results in all but one instance. These results indicate that the protocol employed produced adequate anticoagulation for the bypass procedure in all the patients. Protamine sulphate failed to neutralize heparin adequately after bypass in the 3 patients who received additional heparin during the surgical procedure. The monitoring of heparin activity during and after extracorporeal circulation is a desirable addition to open-heart surgical treatment.
...
PMID:The monitoring of heparin activity during extracorporeal circulation. 88 33
In 34 patients with severe burn injuries platelets, fibrinogen, prothrombin time, partial
thromboplastin
time,
thrombin
time and factor XIII were measured daily. Half of the patients were administered 15 000 IE of heparin per 24 hours. In the first 4 days there was a rapid fall of factor XIII to a value of approximately 30%. Values remained very low during the whole observation period of up to 20 days. However, in patients treated with heparin, values tended to be 10--15% higher. After an initial decline on the tenth day, the platelets had risen to the lowest normal level. Platelets were identical in both groups. The causes for the changes in these haemostasis parameters, their significance, and possible consequences of therapy are discussed.
...
PMID:[Factor XIII deficiency in burns]. 90 34
Ten patients suffering from degenerative arthropathies were treated to demonstrate a significant influence of suppositoroes containing 500 mg mucopolysaccharide polysulfuric acid ester on certain clotting parameters such as plasma recalcification time, partial
thromboplastin
time and
thrombin
time. These investigations had been preceeded by blank determinations and tests with suppositories containing 250 and 400 mg resp. of active substance. It could be shown that the active substance is absorbed even if the substance is applied rectally in form of suppositories if these contain sufficient doses of MPS. Consequently, suppositories containing MPS could be used for a therapy of degenerative arthropathies whenever intraarticular and periarticular or intramuscular administration are not possible.
...
PMID:[1st studies on the problem of rectal resorption of MPS in the treatment of arthroses]. 91 90
The DIC syndrome is the most common cause of an abnormal hemorrhage tendency during pregnancy and the puerperium and reflects systemic activation of the coagulation cascade by circulating thromboplastic material, with secondary activation of the fibrinolytic system. Its presence in a pregnant patient almost invariably is evidence of an underlying obstetric disorder such as abruptio placentae, eclampsia, retention of a dead fetus, amniotic fluid embolism, placental retention or bacterial sepsis. Diagnosis of the DIC syndrome rests on the demonstration of reduced levels of fibrinogen and platelets, prolongation of the
thrombin
, prothrombin and partial
thromboplastin
times, and the presence of fibrin/fibrinogen degradation products (FDP) in the serum. Therapy consists of prompt removal of the source of procoagulant material, replacement of depleted clotting factors and, in some cases, anti-coagulation with heparin.
...
PMID:Disseminated intravascular coagulation in pregnancy. 91 82
Besides a thermolabile inhibitor of tissue
thromboplastin
a thermostable inhibitor was found in human blood serum; molecular weight of the inhibitor (estimated by gel filtration) is 210000-235000 daltons, while molecular weight of a thermolabile inhibitor--480000 daltons. Inhibition of the
thrombin
formation system by the termostable inhibitor was reversible and was characterized kinetically as a mixed type of inhibition. Both inhibitors were found in blood of rats. Their content varied irrespectively of the state of hemocoagulation. Content of the thermostable inhibitor was distinctly decreased in blood serum after the blockade of reticuloendothelial system by administration of tripane blue.
...
PMID:[Serum thermostable and thermolabile inhibitors of tissue thromboplastin]. 91 77
Serial measurements of coagulation activity, platelet counts, and platelet aggregation were done in patients with full-thickness burns involving 25% or more of body surface area to detect specific changes that might correlate with the onset of septicemia. Mean and maximal values for prothrombin time, partial
thromboplastin
time,
thrombin
time, activities of factor V and factor VIII, and concentrations of fibrinogen and fibrinogen-related antigens observed in the presence of bacterial septicemia did not differ significantly from those observed in the absence of septicemia. Mean platelet counts were significantly less with sepsis, but values in individual subjects were not indicative of the presence of septicemia. By contrast, platelet aggregation in response to adenosine diphosphate, epinephrine, and collagen always became severely abnormal with the onset of septicemia but not in the absence of sepsis.
...
PMID:Platelet aggregation as a sign of septicemia in thermal injury. A prospective study. 94 30
Human lymphocytes stimulated with concanavalin-A produce a coagulant activity which decreases the clotting time as expressed through the recalcification time of citrated plasma, the partial
thromboplastin
time, the
thrombin
clotting time of citrated plasma and the
thrombin
clotting time of fibrinogen solutions. The culture supernatants of human lymphocytes stimulated with concanavalin-A also have a direct coagulant effect on human fibrinogen solution. They decrease the lag period of recalcification time of citrated plasma but do not modify the duration of polymerization as measured with a spectrophotometric method.
...
PMID:Lymphokines and thrombosis. II. Procoagulant activity produced by human lymphocytes stimulated with concanavalin A (con-A). 94 36
Heparinless venoarterial bypass (HL-VAB) was carried out in 16 sheep for 6 days, by means of a closed circuit tubing coated with nonthrombogenic polyurethane-polyvinyl-graphite (PPG) and a roller pump. Nine experiments were completed uneventfully. Seven sheep died during bypass. The causes of death were pneumonia (2), caseous granulomatous lung abscess (3) or abdominal abscess (1), and thromboembolism (1). The last complication was caused by inadverten trauma to the PPG coating at the time of tubing connection. In the animals in which HL-VAB was uneventful, no significant changes were noted in the hematologic studies including white blood counts, platelet counts, hematocrit, plasma fibrinogen levels, prothrombin time,
thrombin
time, activated partial
thromboplastin
time, Factors V and VIII, and free plasma hemoglobin levels. Inconsistant changes in the above parmeters were noted in the animals which died of complications. In conclusion, prolonged HL-VAB has no adverse effects on blood coagulation mechanism.
...
PMID:Blood coagulation studies during six day heparinless venoarterial bypass in sheep. 94 98
Blood clotting and fibrinolytic systems were studied in the plasma of a sei whale (Balaenoptera borealis). The sei whale belongs to the suborder baleen whales of the order Cetacea. Whale plasma had a greatly prolonged kaolin-activated partial
thromboplastin
time and was deficient in Hageman factor (factor XII), Fletcher factor (a plasma prekallikrein), and PTA (factor XI). All other clotting factor activities were present in amounts comparable to that of normal human plasma. Whale plasminogen was activated by human urokinase, but not by streptokinase. Whale plasma contained inhibitory activities against
thrombin
, activated Stuart factor, activated PTA, activated Fletcher factor, and plasmin.
...
PMID:Studies on the blood clotting and fibrinolytic system in the plasma from a sei (baleen) whale. 96 76
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>